Advertisement
Singapore markets open in 7 hours 59 minutes

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,032.43
    -39.20 (-0.77%)
     

  • Dow

    37,999.45
    -461.47 (-1.20%)
     

  • Nasdaq

    15,542.09
    -170.66 (-1.09%)
     

  • Bitcoin USD

    64,418.55
    -315.05 (-0.49%)
     

  • CMC Crypto 200

    1,387.15
    +4.58 (+0.33%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Gold

    2,342.60
    +4.20 (+0.18%)
     

  • Crude Oil

    82.61
    -0.20 (-0.24%)
     

  • 10-Yr Bond

    4.6960
    +0.0440 (+0.95%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Sanofi acquires over-the-counter rights for Cialis

Sanofi acquires rights to sell Eli Lilly's Cialis ED drug without a doctor's prescription

The Associated Press

French drugmaker Sanofi is buying the rights to seek approval for a version of the erectile dysfunction drug Cialis that customers would be able to buy without a doctor's prescription.

Sanofi will acquire the rights from its U.S. counterpart Eli Lilly and Co. for the United States, Europe, Canada and Australia under the deal.

Lilly spokeswoman Celeste Stanley says they don't expect to launch such a version before 2018.

Cialis is currently sold only through prescription. It brought in $2.16 billion in worldwide sales last year, but it will lose patent protection in the U.S. and other markets in 2017. That will expose the drug to competition from cheaper, generic versions.

Terms of the Sanofi-Lilly deal were not disclosed.